These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23540938)

  • 21. An industrial approach towards solid dosage development for first-in-human studies: Application of predictive science and lean principles.
    Kalaria DR; Parker K; Reynolds GK; Laru J
    Drug Discov Today; 2020 Mar; 25(3):505-518. PubMed ID: 31926318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active pharmaceutical ingredient (API) production involving continuous processes--a process system engineering (PSE)-assisted design framework.
    Cervera-Padrell AE; Skovby T; Kiil S; Gani R; Gernaey KV
    Eur J Pharm Biopharm; 2012 Oct; 82(2):437-56. PubMed ID: 22820647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 3D Printing Pharmaceuticals: Drug Development to Frontline Care.
    Trenfield SJ; Awad A; Goyanes A; Gaisford S; Basit AW
    Trends Pharmacol Sci; 2018 May; 39(5):440-451. PubMed ID: 29534837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of pharmacokinetic and pharmacokinetic/pharmacodynamic modeling in drug discovery and development.
    Yu XQ; Wilson AG
    Future Med Chem; 2010 Jun; 2(6):923-8. PubMed ID: 21426110
    [No Abstract]   [Full Text] [Related]  

  • 25. Application of in silico, in vitro and preclinical pharmacokinetic data for the effective and efficient prediction of human pharmacokinetics.
    Grime KH; Barton P; McGinnity DF
    Mol Pharm; 2013 Apr; 10(4):1191-206. PubMed ID: 23253040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Applications of high-throughput ADME in drug discovery.
    Kassel DB
    Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case study: technology initiative led to advanced lead optimization screening processes at Bristol-Myers Squibb, 2004-2009.
    Zhang L; Cvijic ME; Lippy J; Myslik J; Brenner SL; Binnie A; Houston JG
    Drug Discov Today; 2012 Jul; 17(13-14):733-40. PubMed ID: 22425710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring activity cliffs in medicinal chemistry.
    Stumpfe D; Bajorath J
    J Med Chem; 2012 Apr; 55(7):2932-42. PubMed ID: 22236250
    [No Abstract]   [Full Text] [Related]  

  • 29. Evolution of ADME science: where else can modeling and simulation contribute?
    Smith DA
    Mol Pharm; 2013 Apr; 10(4):1162-70. PubMed ID: 23294153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines.
    Alavijeh MS; Palmer AM
    IDrugs; 2004 Aug; 7(8):755-63. PubMed ID: 15334309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of discovery DMPK scientists in industry: where do we go from here?
    Moriwaki T
    Drug Metab Pharmacokinet; 2012; 27(2):169-70. PubMed ID: 22666880
    [No Abstract]   [Full Text] [Related]  

  • 32. Automation of Drug Discovery through Cutting-edge
    Singh S; Singh PK; Sachan K; Kumar M; Bhardwaj P
    Curr Comput Aided Drug Des; 2024; 20(6):723-735. PubMed ID: 37807412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent In Silico Resources for Drug Design and Discovery.
    Veljkovic N
    Curr Med Chem; 2019; 26(21):3836-3837. PubMed ID: 31584358
    [No Abstract]   [Full Text] [Related]  

  • 34. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Connecting the dots: role of standardization and technology sharing in biological simulation.
    Ghosh S; Matsuoka Y; Kitano H
    Drug Discov Today; 2010 Dec; 15(23-24):1024-31. PubMed ID: 20934535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15.
    Boobis A; Gundert-Remy U; Kremers P; Macheras P; Pelkonen O
    Eur J Pharm Sci; 2002 Dec; 17(4-5):183-93. PubMed ID: 12453607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux.
    Desai PV; Sawada GA; Watson IA; Raub TJ
    Mol Pharm; 2013 Apr; 10(4):1249-61. PubMed ID: 23363443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What happened to the modeling and simulation revolution?
    Bonate PL
    Clin Pharmacol Ther; 2014 Oct; 96(4):416-7. PubMed ID: 25236664
    [No Abstract]   [Full Text] [Related]  

  • 39. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
    Palucki M; Higgins JD; Kwong E; Templeton AC
    J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
    [No Abstract]   [Full Text] [Related]  

  • 40. In silico functional profiling of small molecules and its applications.
    Sato T; Matsuo Y; Honma T; Yokoyama S
    J Med Chem; 2008 Dec; 51(24):7705-16. PubMed ID: 19032081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.